Irrespective of JAK2 V617F driver mutation status, all MPN patients are characterized by dysregulated Janus kinase (JAK)/signal transducer and activator of transcription (STAT) activation, which further contributes to chronic inflammation and cytokine expression [7]. This evidence concerns the gene JAK2 and myeloproliferative disorder.